Top Biotech Companies With Best Stability & Growth (3,307)

Strong Revenue Growth: Recent disclosures highlight year-over-year revenue increases in 2025 and further growth in early 2026, with guidance pointing to continued double-digit expansion. Record analysis volumes and scaling usage underpin this top-line momentum.

Customer Loyalty & Retention: Net Dollar Retention improved and core genomics customers increased through 2025 into Q1 2026, indicating expanding spend and usage within the installed base. These trends suggest effective land-and-expand dynamics as newer applications drive deeper adoption.

Market Expansion: The company is adding a record number of new customers and expanding in the U.S., including large health-system wins and broader adoption of MSK-ACCESS/MSK-IMPACT. Rising platform analyses across regions signal broader geographic traction.

Investor Backing & Capital Strength: Recent Series C and a $50M Series D tied to CT‑155, alongside strategic investment from Medidata/Dassault, indicate strong external support and added runway. Blue‑chip partners attaching capital to commercialization plans reinforce confidence in near‑term execution.

Product Line Growth: FDA clearance and U.S. launch of Rejoyn, FDA authorization for CT‑132, and Phase 3 success for CT‑155 advance the portfolio from development to marketed or near‑market assets. Acquired assets like AspyreRx and the Click SE initiative further broaden offerings.

Strategic Partnerships: Long‑standing collaborations with Otsuka, Boehringer Ingelheim, and Dassault Systèmes/Medidata underpin development, data capabilities, and commercialization pathways. These alliances suggest access to scale and expertise beyond a single company’s resources.

Strong Revenue Growth: Recent disclosures show rising total revenue and accelerating Galleri test volumes year over year, with both full‑year 2025 and early 2026 reporting continued momentum. Quarterly updates point to sustained double‑digit growth across revenue and volumes.

Strategic Partnerships: Announcements detail deeper channel integrations and access, including Epic EHR ordering, Quest connectivity, and collaborations with health systems, employers, and digital‑health platforms. International arrangements, such as a Samsung collaboration and a Canada launch, further extend reach.

Investor Backing & Capital Strength: The company secured additional financing in late 2025 and reports a cash position described as providing a multi‑year runway. Public company status post‑spin‑off offers direct access to capital markets to fund commercialization and regulatory efforts.

Strong Revenue Growth: Independent estimates point to continued ARR increases since 2022, with momentum remaining positive despite a slower pace than earlier hyper‑growth. Feedback suggests growth is ongoing and more disciplined rather than stagnating.

Product Line Growth: Company materials describe hundreds of new capabilities and AI‑powered tools launched through 2024–2025, alongside expanded modules and integrations. This sustained shipping cadence indicates continued investment and expansion of the platform’s surface area.

Strategic Partnerships: Named enterprise announcements include Novonesis adopting the platform across 1,500 scientists and an expanded collaboration with Moderna focused on AI‑driven research. These wins suggest ongoing enterprise adoption and deepening ties with marquee biopharma.

Strong Revenue Growth: Full-year 2025 total revenue increased with software up and drug discovery roughly doubling, and early 2026 showed continued expansion in underlying annual contract value with management guiding higher for the year.

Strategic Partnerships: Multiple new and expanded pharma collaborations and progress in co‑founded companies (e.g., an announced acquisition and positive clinical readouts) provide potential milestone and equity upside that supports growth.

Future-Ready Strategy: The accelerated shift from on‑premises licenses to hosted, ratable contracts aims to increase predictability, complemented by new offerings such as predictive toxicology and an agentic AI co‑scientist to deepen adoption.

Product Line Growth: In May 2026, the company launched Flatiron Telescope, an AI platform generating oncology insights in minutes, and highlighted 25+ ASCO 2026 research acceptances—signals of ongoing product and R&D investment.

Strategic Partnerships: Abbott integrated its precision oncology tests into OncoEMR on March 30, 2026, with similar prior integrations (e.g., Natera in 2025), indicating expanding in‑workflow partnerships across community oncology.

Market Expansion: Disclosures cite 5 million+ de‑identified patient records and multinational activity across the U.S., U.K., Germany, and Japan, alongside a tripled global oncology research network—evidence of growing geographic and dataset reach.

Strong Revenue Growth: Recent results and guidance show steep top-line expansion, with Q1 2026 revenue up year over year and full‑year 2026 outlook raised, indicating continued momentum.

Strategic Partnerships: Collaborations with major pharmaceutical companies and tools providers (e.g., AstraZeneca/Pathos, Merck, Gilead, Illumina, BMS) broaden product reach and support sustained demand.

Diversified Revenue Streams: Growth across Diagnostics and higher‑margin Data & Applications, alongside expanding offerings such as digital pathology and care pathway tools, indicates multiple engines contributing to scale.

Product Line Growth: Company reports that launched and acquired products, including new oncology assets like Padcev, are contributing meaningful growth and momentum. Underlying non‑COVID revenue is increasing, with oncology and other recent launches adding to the base.

Cost & Operational Efficiency: Management indicates cost realignment and manufacturing programs are on track to deliver about $5.7B net savings by end‑2026, supporting margins and reinvestment. These measures provide capacity to fund launches and offset headwinds.

Future-Ready Strategy: The company highlights a sizable late‑stage pipeline and recent strategic acquisitions in oncology and obesity aimed at higher‑growth categories. Plans for numerous pivotal study starts in 2026 and continued pipeline investment position the business for longer‑term growth.

Investor Backing & Capital Strength: Evidence shows a $372M Series D in June 2024 led by a16z with Sanofi participation, one of the larger biotech financings that year. The capital is framed as fuel for acquiring or in-licensing assets and expanding AI capabilities, signaling strong investor confidence.

Strategic Partnerships: A three‑way collaboration with Sanofi and OpenAI announced in May 2024 to build AI software for drug development highlights high‑profile external alignment. Additional partnered activity, such as the 2025 Sanofi deal for gusacitinib, illustrates the company’s model in practice.

Product Line Growth: Since 2025 the portfolio expanded via in‑licensing and asset‑centric subsidiaries, including an anti‑CD226 mAb (IMIDomics), a miR‑124 activator (Kenmare Bio), and ex‑China rights to a CNS‑penetrant TYK2 inhibitor from Lynk. A planned Phase 1 start in H1 2026 underscores near‑term pipeline progression.

Market Expansion: Public disclosures show the site network rising from 5,500+ in September 2025 to 6,000+ across 50+ countries with 25+ sponsors by 2026, indicating steady expansion. Partnerships that add distribution—such as the RealTime eClinical tie-up covering 50+ networks and 2,000+ sites—further broaden reach.

Innovation-Driven Growth: In 2025 the company launched AI patient pre-screening and AI site-selection to accelerate enrollment and improve selection, with 2026 content highlighting added integrations and case studies. The CEO characterized these capabilities as the “biggest boost” to growth.

Investor Backing & Capital Strength: In March 2023 the company raised a $20M Series A2 to fund product innovation, international growth, and hiring. This capital base supports continued go-to-market and platform expansion.

Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.

Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.

Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.

Strong Revenue Growth: Recent results show mid-single-digit underlying growth through 2024–2025, with management reiterating guidance for continued growth in 2026. Early 2026 updates indicate broad-based contributions across units despite some subsegment variability.

Profitability: Trading profit and margins improved, supported by execution of the 12‑Point Plan and the transition to the RISE strategy. Management is guiding to further profit growth alongside higher returns.

Healthy Cash Flow: Free cash flow strengthened in 2025 with guidance for robust generation in 2026. Share repurchases completed and newly announced buybacks signal confidence and disciplined capital allocation.

Innovation-Driven Growth: The company is positioned as a leader in mRNA medicine with multiple late-stage respiratory and oncology programs that could expand beyond COVID into new indications. Acceptance of the flu BLA and positive Phase 3 data for a flu+COVID combo create concrete approval catalysts that could broaden the seasonal franchise if reviews are favorable.

Product Line Growth: The business is transitioning from a single declining product toward a multi-product portfolio, with RSV, next-gen COVID, flu, and combo vaccines advancing toward targeted 2026 approvals. Management’s expectation of modest revenue growth in 2026, with no flu or flu/COVID revenue assumed, implies potential upside if launches land on time.

Strong Market Position & Advantage: The company has demonstrated platform leadership by scaling mRNA globally during COVID and securing a non-COVID mRNA vaccine approval with mRESVIA, including a label expansion to certain higher-risk adults. Settlement of the lipid-nanoparticle patent dispute removes a major legal overhang, improving focus and visibility for launches and late-stage execution.